These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20109135)

  • 21. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
    Fujii S
    Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immuno-oncology-101: overview of major concepts and translational perspectives.
    Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tim-3 and its role in regulating anti-tumor immunity.
    Das M; Zhu C; Kuchroo VK
    Immunol Rev; 2017 Mar; 276(1):97-111. PubMed ID: 28258697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-27 in tumor immunity and immunotherapy.
    Murugaiyan G; Saha B
    Trends Mol Med; 2013 Feb; 19(2):108-16. PubMed ID: 23306374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Role of T cells in tumor immunology and immunotherapy].
    Ladányi A
    Magy Onkol; 2019 Sep; 63(3):165-171. PubMed ID: 31533135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.
    Sayour EJ; Mitchell DA
    J Immunol Res; 2017; 2017():3145742. PubMed ID: 28265580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity.
    Levy ES; Chang R; Zamecnik CR; Dhariwala MO; Fong L; Desai TA
    Mol Pharm; 2021 Mar; 18(3):1014-1025. PubMed ID: 33541072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.
    Payne KK; Bear HD; Manjili MH
    Future Oncol; 2014 Aug; 10(10):1779-94. PubMed ID: 25303057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Biology of Immune-Active Cancers and Their Regulatory Mechanisms.
    Bedognetti D; Cesano A; Marincola FM; Wang E
    Cancer Treat Res; 2020; 180():149-172. PubMed ID: 32215869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach.
    Krijgsman D; Hokland M; Kuppen PJK
    Front Immunol; 2018; 9():367. PubMed ID: 29535734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cooperativity of adaptive and innate immunity: implications for cancer therapy.
    Shanker A; Marincola FM
    Cancer Immunol Immunother; 2011 Aug; 60(8):1061-74. PubMed ID: 21656157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer vaccine development: on the way to break immune tolerance to malignant cells.
    Mocellin S; Rossi CR; Nitti D
    Exp Cell Res; 2004 Oct; 299(2):267-78. PubMed ID: 15350526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
    Butt AQ; Mills KH
    Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
    Iurescia S; Fioretti D; Rinaldi M
    Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.
    Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I
    Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lifting the innate immune barriers to antitumor immunity.
    Rothlin CV; Ghosh S
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cells and cytokines in immune rejection of cancer.
    Ferrantini M; Capone I; Belardelli F
    Cytokine Growth Factor Rev; 2008 Feb; 19(1):93-107. PubMed ID: 18054517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural killer cells and anti-tumor immunity.
    Nicholson SE; Keating N; Belz GT
    Mol Immunol; 2019 Jun; 110():40-47. PubMed ID: 29233542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
    Braza MS; Klein B
    Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.